| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 29 | GR 1 | 99.36 |
| Multiple Myeloma Research and Treatments | Lifetime | 68 | GR 2 | 99.52 |
| Peptidase Inhibition and Analysis | Lifetime | 163 | GR 2 | 99.24 |
| Protein Degradation and Inhibitors | Lifetime | 84 | GR 2 | 99.22 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 245 | GR 1 | 99.28 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 125 | GR 2 | 98.92 |
| Cancer Treatment and Pharmacology | Lifetime | 421 | GR 4 | 98.78 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 314 | GR 1 | 98.50 |
| Lymphoma Diagnosis and Treatment | Lifetime | 706 | GR 2 | 98.32 |
| Neuroendocrine Tumor Research Advances | Lifetime | 756 | GR 2 | 97.62 |
| Bone health and treatments | Lifetime | 639 | GR 4 | 97.22 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 783 | GR 3 | 94.90 |
| Dermatological and Skeletal Disorders | Lifetime | 301 | GR 1 | 94.53 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 577 | GR 3 | 86.00 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 7 | GR 1 | 99.49 |
| Peptidase Inhibition and Analysis | 2021-2025 | 25 | GR 2 | 99.29 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 38 | GR 1 | 99.39 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 32 | GR 2 | 99.60 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 52 | GR 1 | 99.00 |
| Protein Degradation and Inhibitors | 2021-2025 | 109 | GR 4 | 97.58 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 98 | GR 1 | 97.45 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 156 | GR 2 | 96.21 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 525 | GR 3 | 95.58 |
| Cancer Treatment and Pharmacology | 2021-2025 | 317 | GR 3 | 93.71 |
| Parathyroid Disorders and Treatments | 2021-2025 | 208 | GR 1 | 93.12 |
| Cancer Mechanisms and Therapy | 2021-2025 | 195 | GR 4 | 89.48 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 214 | GR 2 | 90.72 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 713 | GR 4 | 85.89 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 647 | GR 6 | 76.63 |
| Hematological disorders and diagnostics | 2021-2025 | 403 | GR 3 | 67.49 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 597 | GR 9 | 64.35 |
| Dermatological and Skeletal Disorders | 2021-2025 | 345 | GR 1 | 62.61 |
| Phytochemical compounds biological activities | 2021-2025 | 940 | GR 2 | 48.41 |
| Natural Product Synthesis and Anticancer Bioactivity | 2021-2025 | 276 | GR 6 | 22.81 |
